Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 450

The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.

The microbiome and gynaecological cancer development, prevention and therapy

Open access
Łaniewski, Paweł, Ilhan, Zehra Esra, Herbst-Kralovetz, Melissa M.·2020·Nature Reviews Urology

Abstract

The female reproductive tract (FRT), similar to other mucosal sites, harbours a site-specific microbiome, which has an essential role in maintaining health and homeostasis. In the majority of women of reproductive age, the microbiota of the lower FRT (vagina and cervix) microenvironment is dominated by Lactobacillus species, which benefit the host through symbiotic relationships. By contrast, the upper FRT (uterus, Fallopian tubes and ovaries) might be sterile in healthy individuals or contain a low-biomass microbiome with a diverse mixture of microorganisms. When dysbiosis occurs, altered immune and metabolic signalling can affect hallmarks of cancer, including chronic inflammation, epithelial barrier breach, changes in cellular proliferation and apoptosis, genome instability, angiogenesis and metabolic dysregulation. These pathophysiological changes might lead to gynaecological cancer. Emerging evidence shows that genital dysbiosis and/or specific bacteria might have an active role in the development and/or progression and metastasis of gynaecological malignancies, such as cervical, endometrial and ovarian cancers, through direct and indirect mechanisms, including modulation of oestrogen metabolism. Cancer therapies might also alter microbiota at sites throughout the body. Reciprocally, microbiota composition can influence the efficacy and toxic effects of cancer therapies, as well as quality of life following cancer treatment. Modulation of the microbiome via probiotics or microbiota transplant might prove useful in improving responsiveness to cancer treatment and quality of life. Elucidating these complex host–microbiome interactions, including the crosstalk between distal and local sites, will translate into interventions for prevention, therapeutic efficacy and toxic effects to enhance health outcomes for women with gynaecological cancers. The female reproductive tract (FRT) harbours a site-specific microbiome. When dysbiosis of the FRT occurs, altered immune and metabolic signalling might lead to gynaecological cancer. In this Review, the authors discuss how dysbiosis could lead to malignancy and how cancer and its treatment can, in turn, affect the FRT microbiome. Finally, they consider how modulation of the microbiome might prove useful in improving responsiveness to cancer treatment and quality of life in women with gynaecological cancers. The majority of bacteria in the female reproductive tract (FRT) reside in the vagina and cervix; however, the upper FRT might have a distinct low-biomass microbiome and site-specific microenvironmental factors. A vaginal microbiome dominated by Lactobacillus species benefits the host, whereas a dysbiotic vaginal microbiome consisting of anaerobic bacteria is linked to numerous gynaecological and obstetric conditions, including gynaecological cancer. Multiple socioeconomic, behavioural, environmental, hormonal and genetic factors can affect the genital microbiome by disrupting homeostasis and promoting dysbiosis; the FRT microbiome is intimately interconnected with other mucosal sites. Emerging evidence suggests that microbial communities within the FRT might contribute to aetiology, disease severity and/or treatment of gynaecological cancers; however, further well-designed, large-cohort and mechanistic studies are needed. The gut microbiome can modulate oestrogen levels and thereby affect carcinogenesis of oestrogen-mediated cancers, might dictate therapeutic efficacy and toxicity for gynaecological cancer and, ultimately, influence quality of life. Vaginal microbiome modulation via probiotics, novel antimicrobials and/or vaginal microbiota transplantation might be a novel approach to the prevention of gynaecological cancers and/or the reduction of vaginal toxicities related to cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41585-020-0286-z

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 228 references

Cited by

See all 450

Metadata

Authors
Łaniewski, P., Ilhan, Z. E., & Herbst-Kralovetz, M. M.
Venue
Nature Reviews Urology
Published
2020-02-18
Volume
17
Issue
4
Pages
232-250
ISSN
  • 1759-4812 (ISSN-L)
  • 1759-4820
OpenAlex
W3007674389
Cited by
450
References
228
FWCI
8.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The microbiome and gynaecological cancer development, prevention and therapy. https://app.cochat.ai/papers/10.1038/s41585-020-0286-z
The paper
Łaniewski, P., Ilhan, Z. E., & Herbst-Kralovetz, M. M. (2020). The microbiome and gynaecological cancer development, prevention and therapy. Nature Reviews Urology. https://doi.org/10.1038/s41585-020-0286-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.